蒽环类抗肿瘤药物的心脏毒性及保护剂的研究进展  

Hot Issues in the Clinical Application of Protective Agents against Cardiac Toxicity Caused by Anthracyclines

作　　者：姜龙[1] 龙浩[1] 王华庆[2] 

机构地区：[1]中山大学肺癌研究中心,广州市510060 [2]天津医科大学附属肿瘤医院

出　　处：《中国肿瘤临床》2011年第16期991-994,共4页Chinese Journal of Clinical Oncology

摘　　要：由于蒽环类药物显著的抗肿瘤作用和广泛的临床应用,其临床应用的安全性越来越受到重视。该类药物的心脏毒性表现为剂量限制性的特点。目前唯一获批的蒽环类药物心脏毒性保护剂只有右丙亚胺,其心脏保护作用已经得到了广泛认可,并被美国临床肿瘤实践指南及其他多种国内外指南推荐应用于蒽环类药物心脏毒性的预防和治疗。有关右丙亚胺的临床应用策略,目前仍存在一定争议。本文探讨了右丙亚胺对蒽环类药物抗肿瘤效价的影响、右丙亚胺用药时机的选择、右丙亚胺临床应用的安全性以及正在研究中的可能具有心脏保护功能的药物。Anthracyclines have attracted growing attention because of their significant anti-cancer effect, safe clinical application, and great market demand. However, the cardiac toxicity of anthracycline limits its dosage. Dexrazoxane is the only approved cardioprotective agent that has been widely accepted. Dexrazoxane has also been recommended by many guidelines in China and overseas, such as the American Society of Clinical Oncology 2008 Clinical Practice Guideline. However, controversy surrounds the details of the clinical use of Dexrazoxane. In this paper, we have discussed the possibility that Dexrazoxane influences anti-tumor efficacy. In addition, we have tackled the administration, safety, and other possible cardioprotective effects of Dexrazoxane.

关 键 词：蒽环类 心脏损伤 药物毒性 保护剂 

分 类 号：R730.5[医药卫生—肿瘤]